Sharron Gargosky - Immutep Limited Insider

Immutep Limited -- USA Stock  

USD 0.04  0.00  0.00%

Chief Technical Officer

Dr. Sharron Gargosky is Chief Technical Officer of Prima Biomed Ltd. and was with Prima BioMed since August 2010. Dr. Gargosky has over 19 years experience in the biotechnology and pharmaceutical industries and has worked in senior positions in organizations that have successfully received FDA approval for orphan drugs. She is responsible for managing the clinical team working on the CVac immunotherapy cancer vaccine. Prior to joining Prima BioMed Dr. Gargosky was a member of ILMU consulting LLC where she provided project management and operational expertise on pharmaceutical drug and biologic development from early research to Phase IV Trials and the FDA approval process. Dr. Gargosky has also previously held the positions of Chief Scientific Officer at Pulse Health LLC in Portland in the USA and Chief Scientific Officer and Senior Vice President of Corporationrationrate Development at Hyperion Therapeutics Inc. in San Francisco. At Ucyclyd Pharma she managed the approval of orphan drug products and the development of the NCE and within Medics Pharmaceuticals the successful BLA submission and approval for Reloxin. As Vice President of Business Development for Diagnostic System Laboratories she was responsible for business expansion through evaluation and implementation of new growth opportunities and patent portfolio management
Age: 50  Executive Since 2012  Ph.D    
61 2 8315 7003  http://www.primabiomed.com.au
Gargosky has a Postdoctoral Fellowship in Pediatric Endocrinology from Stanford University in California, a Ph.D in biochemistry from University of Adelaide in Australia, First Class Honors in Biochemistry from University of Adelaide, and a BS, Biochemistry, Microbiology, Immunology & Virology from University of Adelaide.

Management Efficiency

The company has return on total asset (ROA) of (17.71) % which means that it has lost $17.71 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (32.99) % meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 4.77 M in total debt with debt to equity ratio (D/E) of 22.9 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Immutep Limited has Current Ratio of 7.97 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.

Similar Executives

Found 11 records

EXECUTIVE Since

David RedfernGlaxoSmithKline plc
2008
Jianjun LiuChina Merchants Bank Co Ltd
2013
Qi ZhuChina Merchants Bank Co Ltd
2008
Ju ZhaoChina Merchants Bank Co Ltd
2014
Antonio AbadinIndustria de Diseo Textil S A
2016
Shiqing XuChina Merchants Bank Co Ltd
N/A
Victoria WhyteGlaxoSmithKline plc
2011
Qi LanChina Merchants Bank Co Ltd
2004
Liang WangChina Merchants Bank Co Ltd
2016
Qingbin WangChina Merchants Bank Co Ltd
2011
Karenann TerrellGlaxoSmithKline plc
2017

Entity Summary

Immutep Limited engages in the research, development, and commercialization of medical biotechnology products in Australia. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited is traded on OTC Market in USA.Immutep Limited (PRRUF) is traded on OTC Market in USA. It is located in 95 Pitt Street and employs 31 people.

Immutep Limited Leadership Team

Pete Meyers, Director, MBA
Russell Howard, Director, Ph.D
Larisa Chisholm, Executive
Tom Bloomfield, Executive
YueLing Wong, Chairman
Frederic Triebel, Executive
Deanne Miller, Executive
Sharron Gargosky, Executive, Ph.D
Grant Chamberlain, Director
Lucy Turnbull, Chairman
Marc Voigt, CEO
Matthew Gregorowski, Executive

Stock Performance Indicators

Did you try this?

Run Idea Breakdown Now
   

Idea Breakdown

Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
View All  Next Launch Idea Breakdown

Trending Equities

Currently Active Assets on Macroaxis
F   
 NYQ 
Purchased over 200 shares of
few hours ago
Traded for 10.96
MSFT   
 NMS 
Purchased over 30 shares of
few hours ago
Traded for 96.11
GM   
 NYQ 
Purchased over 70 shares of
few hours ago
Traded for 37.77
DD   
 NYQ 
Purchased over 100 shares of
few hours ago
Traded for 30.6
CRM   
 NYQ 
Purchased over 20 shares of
few hours ago
Traded for 124.06
RKDA   
 NCM 
Purchased over 100 shares of
few hours ago
Traded for 23.82
Additionally take a look at Your Equity Center. Please also try Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.